Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease

作者：Viviane Tabar, Harini Sarva, Andrés M. Lozano, Alfonso Fasano, Suneil K. Kalia, Kenny Yu, Cameron Brennan, Yilong Ma, Shichun Peng, David Eidelberg, M. Tomishima, Stefan Irion, W. Stemple, N. Abid, Antoine Lampron, Lorenz Studer, Claire Henchcliffe · 发表于：Nature · 年份：2025 · DOI：10.1038/s41586-025-08845-y · 被引用次数：131 · 研究领域：Pluripotent Stem Cells Research、Parkinson's Disease Mechanisms and Treatments、Nerve injury and regeneration

Fluoro-DOPA positron emission tomography uptake increased, indicating graft survival. Secondary and exploratory clinical outcomes showed improvement or stability, including improvement in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III OFF scores by an average of 23 points in the high-dose cohort. There were no graft-induced dyskinesias. These data demonstrate safety and support future definitive clinical studies.